Single-stranded AAV vector consisting of a bioengineered capsid, liver-specific promoter, and factor IX Padua (factor IX–R338L) was administered in ten men with hemophilia B who had factor IX coagulant activity of 2%. Here, F9 is linked to hemophilia B.